top of page

Check out our new preprint

I collaboration with Nahum Sonenberg's lab at McGill University (Canada) we report the discovery of a novel mechanism by which SARS-CoV2, the virus that causes COVID19 disease, hijacks a cellular mechanism to block production of the key anti-viral cytokine Interferon-ß.

We previously discovered that the mRNA cap-binding protein 4EHP plays a key role in mediating the repression of mRNA translation induced by microRNAs. This mechanism is also important for fine-tuning the expression of production of Interferon-ß in the cell to avoid unintended over-activation of the immune system.

In this new study, we show that the the Non-Structural Protein 2 (NSP2) produced by SARS-CoV-2 binds the cellular GIGYF2 protein. This interaction enhances the binding of GIGYF2 to 4EHP, thereby repressing translation of the Ifnb1 mRNA and leading to inefficient immune response to viral infection. Our findings reveal a new target for rescuing the antiviral innate immune response to SARS-CoV-

Recent Posts

See All

Ever wonder why SARS-CoV-2 was so successful in infecting different people, even those who were otherwise healthy and had a robust immune system? Part of the reason could be the ability of the virus t

Congratulations to our collaborators at Sossin lab (Montreal Neurological Institute) and Gkogkas lab (Foundation for Research and Technology-Hellas) for publication of their very enticing new paper on

We are starting the new year with the excellent news of Parisa's new paper in bioRXiv . We had shown in the past that the cap-binding protein 4EHP is a critical component of the mechanism that mediate

bottom of page